Lv1
16 积分 2024-11-14 加入
Fruquintinib with programmed cell death ‐ 1 inhibitors versus triflueridine ‐ tipiracil ‐ 102 with bevacizumab in late‐line mCRC : A retrospective cohort study based on propensity score matching
4个月前
已完结
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
4个月前
已完结
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
4个月前
已完结
MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1
5个月前
已完结
MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1
5个月前
已完结
MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1
5个月前
已完结
[Impact of VA-ECMO combined with IABP and timing on outcome of patients with acute myocardial infarction complicated with cardiogenic shock]
6个月前
已完结
Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study
6个月前
已完结
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
6个月前
已完结
皖公网安备34019202002308
